AtriCure Announces Upcoming Investor Conference Schedule
01 November 2014 - 7:02AM
Business Wire
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation and Left Atrial Appendage
Management, today announced that it will present at the Stifel
Healthcare Conference 2014 at the Palace Hotel in New York City on
Tuesday, November 18, 2014. Management is scheduled to present
at 3:35 p.m. Eastern Time. A live audio webcast and replay of
the presentation will be available for 30 days following the
presentation on the Investors page of AtriCure’s corporate website
at www.atricure.com.
AtriCure management is scheduled to present at the Canaccord
2014 Medical Technologies & Diagnostics Forum at the Westin
Grand Central in New York City on Thursday, November 20, 2014.
Management is scheduled to present at 8:30 a.m. Eastern Time. A
live audio webcast and replay of the presentation will be available
for 30 days following the presentation on the Investors page of
AtriCure’s corporate website at www.atricure.com.
AtriCure management is also scheduled to present at the Piper
Jaffray 26th Annual Healthcare Conference at the Palace Hotel in
New York City on Wednesday, December 3, 2014. Management is
scheduled to present at 11:00 a.m. Eastern Time. A live audio
webcast and replay of the presentation will be available for 30
days following the presentation on the Investors page of AtriCure’s
corporate website at www.atricure.com.
About AtriCure,
Inc.AtriCure, Inc. is a medical device company
providing innovative atrial fibrillation (Afib) solutions designed
to produce superior outcomes that reduce the economic and social
burden of atrial fibrillation. AtriCure’s Synergy™ Ablation System
is the first and only surgical device approved for the treatment of
Persistent and Longstanding Persistent forms of Afib in patients
undergoing certain open concomitant procedures. AtriCure’s AtriClip
Left Atrial Appendage Management (LAAM) exclusion device is the
most widely sold device worldwide that’s indicated for the
occlusion of the left atrial appendage. The company believes
cardiothoracic surgeons are adopting its ablation and LAAM devices
for the treatment of Afib and reduction of Afib related
complications such as stroke. Afib affects more than 33.5 million
people worldwide.
AtriCure, Inc.Andy Wade, Vice President and Chief
Financial Officer, 513-755-4564awade@atricure.comorInvestor
Relations ContactWestwicke PartnersLynn Pieper,
415-202-5678lynn.pieper@westwicke.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Apr 2024 to May 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From May 2023 to May 2024